{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T18:01:51Z","timestamp":1784311311156,"version":"3.55.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Although the fibrinogen-to-lymphocyte ratio (FLR) is an established prognostic biomarker in various solid tumors, its role in non-muscle-invasive bladder cancer (NMIBC) remains poorly defined. This study aimed not only to investigate the predictive value of preoperative FLR for overall survival (OS) in NMIBC patients undergoing transurethral resection of bladder tumor (TURBt), but also to develop and validate a novel FLR-based nomogram as a practical clinical tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study enrolled 304 NMIBC patients who underwent TURBt at the Shijiazhuang People\u2019s Hospital between November 2013 and January 2024, with OS as the primary endpoint. The optimal prognostic cutoff for FLR was determined by maximizing the Youden index via receiver operating characteristic (ROC) curve analysis. Propensity score matching (1:2) was employed to balance baseline confounders. The dose-response relationship between continuous FLR and mortality risk was evaluated using restricted cubic splines (RCS), which confirmed a linear association. Subsequently, independent prognostic factors identified through Cox proportional hazards regression were integrated to construct a nomogram. The model\u2019s predictive accuracy and clinical utility were then comprehensively evaluated using the concordance index (C-index), calibration curves, time-dependent ROC curves, and decision curve analysis (DCA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The optimal FLR cutoff was identified as 2.91. Patients in the high-FLR group (FLR \u2265 2.91) exhibited significantly poorer OS (P &amp;lt; 0.001) and cancer-specific survival (CSS; P = 0.004). RCS analysis confirmed a significant positive linear association between increasing FLR levels and all-cause mortality risk. Critically, multivariate Cox regression validated FLR as an independent predictor for both OS (Hazard Ratio (HR): 1.520, 95% Confidence Interval (CI): 1.149-2.010) and CSS (HR: 1.536, 95% CI: 1.033-2.284). Integrating FLR into a baseline model improved the C-index for OS prediction from 0.739 to 0.772. The resulting nomogram demonstrated robust discrimination (C-index: 0.772), excellent calibration, and superior net clinical benefit in DCA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Preoperative FLR is an independent predictor of overall survival in NMIBC, characterized by a robust linear dose-response relationship with mortality risk. This cost-effective biomarker, integrated into our validated nomogram, enhances risk stratification to guide personalized postoperative management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1707696","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T05:14:44Z","timestamp":1769058884000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Preoperative fibrinogen-to-lymphocyte ratio as a prognostic biomarker for non-muscle-invasive bladder cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Xueqiao","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Urology, The People\u2019s Hospital of Shijiazhuang","place":["Shijiazhuang, Hebei, China"]},{"name":"Graduate School, Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqiang","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Urology, The People\u2019s Hospital of Shijiazhuang","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhe","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Medicine and Health, Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifan","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Urology, The People\u2019s Hospital of Shijiazhuang","place":["Shijiazhuang, Hebei, China"]},{"name":"Graduate School, Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongjie","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Urology, The People\u2019s Hospital of Shijiazhuang","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Urology, The People\u2019s Hospital of Shijiazhuang","place":["Shijiazhuang, Hebei, China"]},{"name":"Graduate School, Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, The People\u2019s Hospital of Shijiazhuang","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, The People\u2019s Hospital of Shijiazhuang","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxing","family":"He","sequence":"additional","affiliation":[{"name":"Department of Urology, The People\u2019s Hospital of Shijiazhuang","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhui","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Urology, The People\u2019s Hospital of Shijiazhuang","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, The People\u2019s Hospital of Shijiazhuang","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"BMJ"},{"key":"B4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2009.03.008","article-title":"An overview of coagulation disorders in cancer patients","volume":"19","author":"Kvolik","year":"2010","journal-title":"Surg Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612563","article-title":"The crossroads of the coagulation system and the immune system: interactions and connections","volume":"24","author":"Wilhelm","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11122385","article-title":"Fibrinogen oxidation and thrombosis: shaping structure and function","volume":"11","author":"Nencini","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40425-019-0549-5","article-title":"Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines","volume":"7","author":"M\u00e9n\u00e9trier-Caux","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12885-023-10653-4","article-title":"Diagnostic value of combining preoperative inflammatory markers ratios with CA199 for patients with early-stage pancreatic cancer","volume":"23","author":"Gu","year":"2023","journal-title":"BMC Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-23-481","article-title":"Establishment and validation of a prediction model for gastric cancer with perineural invasion based on preoperative inflammatory markers","volume":"12","author":"Jiang","year":"2023","journal-title":"Transl Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-23-2271","article-title":"Prognostic significance of alterations in fibrinogen level and fibrinogen-to-lymphocyte ratio after radiotherapy on survival outcomes in glioblastoma","volume":"12","author":"Huang","year":"2023","journal-title":"Transl Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S204938","article-title":"A novel preoperative plasma indicator to predict prognoses for patients with esophageal squamous cell carcinoma after radical esophagectomy: fibrinogen-to-lymphocyte ratio","volume":"11","author":"Fan","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S266653","article-title":"Fibrinogen\/lymphocyte count ratio can be used as a new indicator of prognosis in patients with hepatocellular carcinoma after radical resection","volume":"12","author":"Li","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1274635","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio in patients with non-muscle-invasive bladder cancer with intravesical bacillus Calmette-Gu\u00e9rin immunotherapy: a systematic review and meta-analysis","volume":"14","author":"Huang","year":"2023","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S269244","article-title":"Plasma fibrinogen predicts the prognosis of bladder cancer patients after radical cystectomy","volume":"12","author":"Yang","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1001-9030.2018.09.005","article-title":"Relationship between preoperative plasma fibrinogen and clinicopathological features and prognosis in patients with non-muscle-invasive bladder cancer","volume":"35","author":"Zhang","year":"2018","journal-title":"Chin J Exp Surg"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.07.013","article-title":"Role of the coagulation system in genitourinary cancers: review","volume":"15","author":"John","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13271","article-title":"Role of coagulation factors in urological Malignancy: a prospective, controlled study on prostate, renal and bladder cancer","volume":"24","author":"Alevizopoulos","year":"2017","journal-title":"Int J Urol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3465","article-title":"Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin \u03b1(M)\u03b2(2) engagement of fibrinogen","volume":"70","author":"Steinbrecher","year":"2010","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv546","article-title":"Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer","volume":"27","author":"Joseph","year":"2016","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1707696\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:42:17Z","timestamp":1771918937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1707696\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":22,"alternative-id":["10.3389\/fonc.2026.1707696"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1707696","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"article-number":"1707696"}}